iRhythm Technologies, Inc.: Business Overview, Financials & Competitive Analysis
iRhythm Technologies, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Market-leading digital cardiac diagnostics company with strong growth trajectory, FCF inflection, and significant TAM expansion potential to 27M+ patients. iRhythm demonstrates strong market dominance with 30%+ market share, achieving FCF profitability in 2025 after years of investment. The company has a defensible technology moat through proprietary algorithms and serves.
What is iRhythm Technologies, Inc.'s industry? iRhythm Technologies, Inc. (irhythmtech.com) operates in Digital Healthcare / Medical Devices - Ambulatory Cardiac Monitoring. AskCyborg classifies iRhythm Technologies, Inc. under Digital Healthcare / Medical Devices - Ambulatory Cardiac Monitoring in its company registry.
iRhythm (Nasdaq: IRTC) is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. The company generates nearly all its revenue by providing a complete, end-to-en...
Cyborg Score thesis
Market-leading digital cardiac diagnostics company with strong growth trajectory, FCF inflection, and significant TAM expansion...
Read the full analyst-debate transcript →Get the Latest iRhythm Technologies, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeiRhythm Technologies, Inc. Overview
Pro stress-test →iRhythm (Nasdaq: IRTC) is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. The company generates nearly all its revenue by providing a complete, end-to-end ambulatory cardiac monitoring service, primarily through its Zio platform. iRhythm combines wearable patch technology with AI-driven cloud analytics for remote cardiac monitoring and arrhythmia diagnosis.
Strategic Profile
Pro stress-test →This company is dominating the ambulatory cardiac monitoring market with its Zio platform, which combines a simple wearable patch with powerful, AI-driven cloud analytics, effectively capturing over 30% of the core market share and serving more than 2 million patients annually. The company is projected to be free cash flow positive for the full year 2025, a major milestone that proves the business model's underlying financial health and scalability.
Competitive Landscape
Pro stress-test →InfoBionic.Ai, Philips, Medicomp, Barostim, and Vpatch are some of the 15 competitors of iRhythm Technologies. iRhythm's integrated patch-and-AI platform provides competitive advantage over traditional Holter monitor and mobile telemetry competitors. The company's proprietary algorithms and established provider network create switching costs.
Industry Context
iRhythm Technologies, Inc. operates in Digital Healthcare / Medical Devices - Ambulatory Cardiac Monitoring.
Key facts
Founded: 2006 · Headquarters: San Francisco, US · Revenue: $703M · Market cap: $5.86B